TIME TO EXPAND THE USE OF CASIRIVIMAB/IMDEVIMAB MONOCLONAL ANTIBODY THERAPY? A CASE OF COMPASSIONATE USE IN SEVERE COVID-19 PNEUMONIA

Category Primary study
JournalChest
Year 2022
This article has no abstract
Epistemonikos ID: bf698497453bcab4d3e34de401a63bab64c9f0c0
First added on: Feb 15, 2025